Obstructive hypertrophic cardiomyopathy is a leading cause of heart-related disability in younger adults and the most common cause of sudden death in young athletes.Researchers from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine and collaborators around the globe have published a study in Circulation: Genomic and Precision Medicine that shows that mavacamten used as a standalone therapy, without beta-blockers or calcium-channel blockers, significantly improves symptoms and cardiac obstruction in people with obstructive hypertrophic cardiomyopathy.
HCM, a hereditary condition, is a leading cause of heart-related disability in younger adults. In this progressive heart disease, the heart muscle abnormally thickens and stiffens, blocking blood flow from the left ventricle to the aorta. For decades, treatment has relied on long-standing drugs like beta-blockers, which help symptoms but do not directly target the biology of the disease.
What does it mean for patients?
- Mavacamten monotherapy is effective and safe in real-world practice.
- Many patients can reduce or discontinue background HCM medications.
- Benefits were consistent across diverse racial and ethnic groups.
- Cardiac myosin inhibition may move earlier in the treatment pathway.
Mavacamten is developed to specifically counteract excessive cardiac muscle contraction and represents a new class of precision therapeutics. Until now, evidence supporting its use as monotherapy outside clinical trials has been limited. To address this gap, the present study draws on real‑world clinical data from 278 patients across five countries in the mavaCamten ObservationaL evIdence Global cOnsortium (COLLIGO-HCM) to generate broadly applicable insights.
“The study provides the first global evidence that mavacamten alone can meaningfully reduce outflow tract obstruction and improve symptoms in routine clinical practice,” said Pankaj Arora, M.D., senior author and director of the UAB Cardiogenomics Clinic. “The improvements we observed are consistent across multiple health systems and patient populations, including groups historically underrepresented in clinical trials.”
Pankaj Arora, M.D., director of the UAB Cardiogenomics ClinicAcross the nine-month follow-up period, 60 percent of patients treated with mavacamten monotherapy improved by at least one New York Heart Association class, and outflow tract gradients fell by 35-59 mmHg on average, bringing most patients below guideline thresholds for obstruction. Importantly, systolic function remained stable, and treatment interruptions for reduced ejection fraction were uncommon and largely reversible.
Co-author Garima Arora, M.D., co-director of the UAB Cardiogenomics Clinic, emphasized the practice-changing implications.
“These findings show that many patients may not need multiple medications,” she said. “A single targeted therapy can offer strong clinical benefits while simplifying care.”
“This is more than a therapeutic advance; it is a glimpse into the future of precision cardiology,” Arora said. “Real-world data like these help clinicians make confident, patient-centered decisions.”
According to the authors, continued expansion of access to genetic testing, advanced imaging and precision therapeutics could ensure that patients across all communities benefit from the growing era of targeted cardiovascular care.